Cargando…
Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania
OBJECTIVE: To quantify preferences for preventive therapies for rheumatoid arthritis (RA) across three countries. METHODS: A web-based survey including a discrete choice experiment was administered to adults recruited via survey panels in the UK, Germany and Romania. Participants were asked to assum...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891433/ https://www.ncbi.nlm.nih.gov/pubmed/36068022 http://dx.doi.org/10.1093/rheumatology/keac397 |
_version_ | 1784881135000485888 |
---|---|
author | Simons, Gwenda Veldwijk, Jorien DiSantostefano, Rachael L Englbrecht, Matthias Radawski, Christine Bywall, Karin Schölin Valor Méndez, Larissa Hauber, Brett Raza, Karim Falahee, Marie |
author_facet | Simons, Gwenda Veldwijk, Jorien DiSantostefano, Rachael L Englbrecht, Matthias Radawski, Christine Bywall, Karin Schölin Valor Méndez, Larissa Hauber, Brett Raza, Karim Falahee, Marie |
author_sort | Simons, Gwenda |
collection | PubMed |
description | OBJECTIVE: To quantify preferences for preventive therapies for rheumatoid arthritis (RA) across three countries. METHODS: A web-based survey including a discrete choice experiment was administered to adults recruited via survey panels in the UK, Germany and Romania. Participants were asked to assume they were experiencing arthralgia and had a 60% chance of developing RA in the next 2 years and completed 15 choices between no treatment and two hypothetical preventive treatments. Treatments were defined by six attributes (effectiveness, risks and frequency/route of administration) with varying levels. Participants also completed a choice task with fixed profiles reflecting subjective estimates of candidate preventive treatments. Latent class models (LCMs) were conducted and the relative importance of attributes, benefit–risk trade-offs and predicted treatment uptake was subsequently calculated. RESULTS: Completed surveys from 2959 participants were included in the analysis. Most participants preferred treatment over no treatment and valued treatment effectiveness to reduce risk more than other attributes. A five-class LCM best fitted the data. Country, perceived risk of RA, health literacy and numeracy predicted class membership probability. Overall, the maximum acceptable risk for a 40% reduction in the chance of getting RA (60% to 20%) was 21.7%, 19.1% and 2.2% for mild side effects, serious infection and serious side effects, respectively. Predicted uptake of profiles reflecting candidate prevention therapies differed across classes. CONCLUSION: Effective preventive pharmacological treatments for RA were acceptable to most participants. The relative importance of treatment attributes and likely uptake of fixed treatment profiles were predicted by participant characteristics. |
format | Online Article Text |
id | pubmed-9891433 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-98914332023-02-02 Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania Simons, Gwenda Veldwijk, Jorien DiSantostefano, Rachael L Englbrecht, Matthias Radawski, Christine Bywall, Karin Schölin Valor Méndez, Larissa Hauber, Brett Raza, Karim Falahee, Marie Rheumatology (Oxford) Clinical Science OBJECTIVE: To quantify preferences for preventive therapies for rheumatoid arthritis (RA) across three countries. METHODS: A web-based survey including a discrete choice experiment was administered to adults recruited via survey panels in the UK, Germany and Romania. Participants were asked to assume they were experiencing arthralgia and had a 60% chance of developing RA in the next 2 years and completed 15 choices between no treatment and two hypothetical preventive treatments. Treatments were defined by six attributes (effectiveness, risks and frequency/route of administration) with varying levels. Participants also completed a choice task with fixed profiles reflecting subjective estimates of candidate preventive treatments. Latent class models (LCMs) were conducted and the relative importance of attributes, benefit–risk trade-offs and predicted treatment uptake was subsequently calculated. RESULTS: Completed surveys from 2959 participants were included in the analysis. Most participants preferred treatment over no treatment and valued treatment effectiveness to reduce risk more than other attributes. A five-class LCM best fitted the data. Country, perceived risk of RA, health literacy and numeracy predicted class membership probability. Overall, the maximum acceptable risk for a 40% reduction in the chance of getting RA (60% to 20%) was 21.7%, 19.1% and 2.2% for mild side effects, serious infection and serious side effects, respectively. Predicted uptake of profiles reflecting candidate prevention therapies differed across classes. CONCLUSION: Effective preventive pharmacological treatments for RA were acceptable to most participants. The relative importance of treatment attributes and likely uptake of fixed treatment profiles were predicted by participant characteristics. Oxford University Press 2022-09-07 /pmc/articles/PMC9891433/ /pubmed/36068022 http://dx.doi.org/10.1093/rheumatology/keac397 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Clinical Science Simons, Gwenda Veldwijk, Jorien DiSantostefano, Rachael L Englbrecht, Matthias Radawski, Christine Bywall, Karin Schölin Valor Méndez, Larissa Hauber, Brett Raza, Karim Falahee, Marie Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania |
title | Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania |
title_full | Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania |
title_fullStr | Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania |
title_full_unstemmed | Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania |
title_short | Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania |
title_sort | preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the uk, germany and romania |
topic | Clinical Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891433/ https://www.ncbi.nlm.nih.gov/pubmed/36068022 http://dx.doi.org/10.1093/rheumatology/keac397 |
work_keys_str_mv | AT simonsgwenda preferencesforpreventivetreatmentsforrheumatoidarthritisdiscretechoicesurveyintheukgermanyandromania AT veldwijkjorien preferencesforpreventivetreatmentsforrheumatoidarthritisdiscretechoicesurveyintheukgermanyandromania AT disantostefanorachaell preferencesforpreventivetreatmentsforrheumatoidarthritisdiscretechoicesurveyintheukgermanyandromania AT englbrechtmatthias preferencesforpreventivetreatmentsforrheumatoidarthritisdiscretechoicesurveyintheukgermanyandromania AT radawskichristine preferencesforpreventivetreatmentsforrheumatoidarthritisdiscretechoicesurveyintheukgermanyandromania AT bywallkarinscholin preferencesforpreventivetreatmentsforrheumatoidarthritisdiscretechoicesurveyintheukgermanyandromania AT valormendezlarissa preferencesforpreventivetreatmentsforrheumatoidarthritisdiscretechoicesurveyintheukgermanyandromania AT hauberbrett preferencesforpreventivetreatmentsforrheumatoidarthritisdiscretechoicesurveyintheukgermanyandromania AT razakarim preferencesforpreventivetreatmentsforrheumatoidarthritisdiscretechoicesurveyintheukgermanyandromania AT falaheemarie preferencesforpreventivetreatmentsforrheumatoidarthritisdiscretechoicesurveyintheukgermanyandromania |